Press release: Microcoat announces agreement with Olink to offer innovative proteomic approaches with Olink® Proximity Extension Assay (PEA) technology for pharma partners.
Bernried, Microcoat today announced an agreement with Olink Holding AB to offer innovative proteomic approaches with Olink® Proximity Extension Assay (PEA) by using Olink’s platform (Olink® Target 48). It enables high-throughput, multiplex immunoassays of proteins using minimal volumes of serum, plasma, or almost any other type of biological sample.
“Olink enables Microcoat to broaden its product portfolio in Germany and EMEA for offering proteomic studies with our innovative technology” said Karsten Strauss, PhD, Director, Strategic Accounts, EMEA, Olink Proteomics. “We are proud to have Microcoat as our first service provider in Germany under qualified conditions in order to translate our philosophy of serving the global protein biomarker research market into action within Europe.”
“This agreement with Olink will enable us to provide our pharma clients with end-to-end multi-omic clinical studies in different fields under highest qualified conditions” said Sonja Molinaro, PhD, Managing Director of Microcoat. “This cooperation will allow us to further enhance quality data and excellent operational management, which will differentiate us from other providers in the market. Furthermore, Olink® Target 48 will enable us absolute quantification for clinical trials.”
The next step will be in house validation of the Olink platforms (Olink® Target 48/96), which will allow global and local pharmaceutical companies to enlarge their clinical studies by proteomics measurements under validated conditions.
Microcoat is a B2B company dedicated to offering a wide range of individual and specialized services for the diagnostic and pharmaceutical industry under highest quality levels. Microcoat acts in the Business Segment „Contract Manufacturing“ as approved OEM manufacturer for diagnostic test kits, bulk and finished components according to ISO and IVD standards. In the Business Segment „ Custom Development“ innovative diagnostic immuno- and molecular assays, test components and new test formats are developed according to customer`s requirements. In the Business Segment „Laboratory Services“ the services range from large molecule drug development according to GLP and GCP standards including development, transfer and validation of PK, ADA and Biomarker assays on various platforms. Special service is provided in the fields of endotoxin and pyrogen testing (exploratory or GMP).
Dr. Ingrid Wanninger
Manager Business Development
Mobile: +49 171 3146711
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.